Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Besremi (ropeginterferon alfa-2b)
- etranacogene dezaparvovec
Interactions between your drugs
ropeginterferon alfa-2b etranacogene dezaparvovec
Applies to: Besremi (ropeginterferon alfa-2b), etranacogene dezaparvovec
Etranacogene dezaparvovec can cause liver problems, which may make the medication less effective in treating your condition. Using other medications that can also affect the liver such as ropeginterferon alfa-2b after receiving etranacogene dezaparvovec may increase that risk. Symptoms of liver problems include fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes. Blood tests to monitor liver function should be performed before and after treatment with etranacogene dezaparvovec. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Intron A
Intron A is used for angioblastoma, condylomata acuminata, conjunctival mucosa-associated lymphoid ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
PegIntron
PegIntron is used to treat chronic hepatitis C in adults. Learn about side effects, interactions ...
Sylatron
Sylatron (peginterferon alfa-2b) used to prevent malignant melanoma from coming back after it has ...
Ropeginterferon alfa-2b
Ropeginterferon alfa-2b is used for polycythemia vera
Peginterferon alfa-2b
Peginterferon alfa-2b is used for chronic myelogenous leukemia, hepatitis b, hepatitis c, melanoma ...
Interferon alfa-2b
Interferon alfa-2b is used for angioblastoma, condylomata acuminata, conjunctival mucosa-associated ...
Ruxolitinib
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV) ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.